Aldeyra Therapeutics, Inc. ALDX R2K

Healthcare · Biotechnology · United States

https://www.aldeyra.com

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Market & Price

Market Cap

$105.56M

Current Price

$1.75

High / Low (52W)

$5.89 / $1.24

Beta

1.15

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.70

Price to Book

2.50

P/S

EV/EBITDA

-1.99

Dividend Yield

Profitability & Returns

ROCE

-72.18%

ROE

-51.76%

ROA

-22.22%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.06

EPS (TTM)

$-0.45

Balance Sheet & Liquidity

Debt/Equity

0.37

Quick Ratio

2.67

Current Ratio

2.72

Debt

$15.51M

Total Assets

$72.06M

Current Assets

$71.78M

Working Capital

$43.97M

Ownership

Promoter Holding

3.18%

Chg in Prom Hold

0.00%

FII / Inst Holding

62.79%

Chg in FII Hold

0.03%

Financial Snapshot

Enterprise Value

$56.07M

Total Revenue (TTM)

EBITDA

$-28.13M

Free Cash Flow

$-19.60M

Operating Cash Flow

$-25.99M

Shares Outstanding

60.32M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

15.14%

Revenue (YoY)

Earnings (YoY)

PROS

Profit CAGR of 15.1% over 5 years.

CONS

Trading 70.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ALDX Aldeyra Therapeutics, Inc. R2K	1.75	-	$105.56M	-	-72.18%	-51.76%	-	15.14%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.43M	10.17M	8.00M	6.67M	3.55M
Operating Income	-985.69K	-1.17M	-1.24M	-1.65M	-1.97M	-2.11M	-2.20M	-3.34M	-4.97M	-4.30M	-4.78M	-5.10M	-5.33M	-5.02M	-8.49M	-9.17M	-10.95M	-17.43M	-13.73M	-19.02M	-9.64M	-7.11M	-8.39M	-10.83M	-14.54M	-15.44M	-16.48M	-17.71M	-14.78M	-16.80M	-10.34M	-9.55M	-9.39M	-18.01M	-	-10.43M	-10.17M	-8.00M	-6.67M	-3.55M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9.39M	-9.23M	-7.15M	-5.92M	-2.92M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	483.53K	470.62K	475.90K	475.26K	468.68K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9.93M	-9.77M	-7.69M	-6.46M	-3.45M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1.57M	9.31M	401.77K	-1.14M	-2.01M	-2.14M	-2.23M	-3.37M	-4.97M	-4.30M	-4.78M	-5.09M	-5.31M	-4.99M	-8.40M	-9.05M	-10.81M	-15.62M	-13.33M	-18.72M	-9.87M	-7.52M	-8.87M	-11.29M	-14.94M	-15.79M	-16.79M	-17.78M	-14.55M	-15.62M	-8.99M	-8.19M	-8.08M	-16.85M	-	-9.93M	-9.77M	-7.69M	-6.46M	-3.45M
Diluted EPS	-5.47	-9.81	-4.04	-1.56	-0.36	-0.32	-0.27	-0.35	-0.51	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.28	-0.27	-0.29	-0.30	-0.25	-0.27	-0.15	-0.14	-0.14	-0.28	-0.25	-0.17	-0.16	-0.13	-	-0.06
R&D Expense	325.05K	666.04K	444.28K	663.91K	1.20M	1.14M	1.25M	2.08M	3.51M	2.83M	3.38M	3.37M	3.85M	3.54M	6.60M	6.79M	7.88M	7.85M	10.66M	16.22M	6.63M	4.89M	6.13M	7.73M	11.47M	12.89M	12.23M	14.57M	11.54M	11.24M	6.96M	6.96M	6.18M	14.97M	12.44M	7.42M	8.51M	5.43M	-	2.41M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	62.68M	42.79M	60.12M	35.27M
Operating Income	-3.68M	-7.27M	-11.99M	-18.70M	-22.49M	-39.70M	-63.07M	-36.42M	-	-62.68M	-42.79M	-60.12M	-35.27M
EBITDA	-	-	-	-	-	-	-	-	-	-60.07M	-35.21M	-53.68M	-31.69M
Interest Expense	-	-	-	-	-	-	-	-	-	1.69M	2.07M	1.93M	1.91M
Pretax Income	-	-	-	-	-	-	-	-	-	-62.02M	-37.54M	-55.85M	-33.85M
Tax Provision	-	-	-	-	-	-	-	-	0	-	-	-	-
Net Income	13.06M	-5.19M	-12.09M	-18.70M	-22.34M	-38.89M	-60.83M	-37.55M	-	-62.02M	-37.54M	-55.85M	-33.85M
Diluted EPS	-17.61	-3.09	-1.40	-	-	-	-	-	-	-1.06	-0.64	-0.94	-0.56
R&D Expense	1.54M	3.71M	7.57M	13.18M	16.30M	29.82M	44.35M	24.68M	44.94M	47.31M	29.46M	48.22M	25.66M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	15.14%
1 Year:	-

Stock Price Performance

1 Year:	-18.60%
6 Months:	-66.73%
3 Months:	-67.95%
1 Month:	+16.67%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Jan 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	3.74M	8.79M	28.20M	-	25.19M	44.17M	95.09M	75.52M	83.35M	-	181.29M	148.33M	104.61M	72.06M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	181.02M	147.81M	104.07M	71.78M
Cash & Equivalents	1.22M	3.26M	8.53M	14.65M	14.65M	12.02M	20.02M	47.36M	44.43M	77.86M	-	144.42M	142.82M	54.53M	70.04M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	28.77K	3.24M	0	-	-
Total Liabilities	-	5.65M	2.50M	3.33M	-	3.54M	4.57M	8.47M	27.44M	23.84M	-	30.28M	28.53M	33.60M	27.81M
Current Liabilities	-	605.01K	1.33M	2.12M	-	2.30M	3.35M	8.47M	12.91M	12.41M	-	15.36M	22.26M	18.60M	27.81M
Long Term Debt	-	1.13M	1.18M	1.21M	-	1.24M	1.22M	-	14.53M	11.43M	15.50M	14.92M	-	15.00M	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	16.08M	15.66M	15.30M	15.53M
Total Equity	-54.38M	-40.22M	6.28M	24.88M	24.88M	21.65M	39.60M	86.62M	48.08M	59.51M	-	151.01M	119.80M	71.00M	44.25M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	58.56M	59.20M	59.65M	60.16M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-19.22M	-29.86M	-44.98M	-37.49M	-	-56.64M	-30.33M	-43.21M	-33.35M
Investing Cash Flow	-	-	-	-10.20M	-23.34M	18.48M	29.02M	-	-29.95M	30.00M	-44.92M	47.74M
Financing Cash Flow	-	-	-	37.43M	80.53M	23.58M	41.90M	-	1.22M	-1.27M	-171.42K	1.12M
Capital Expenditure	-14.06K	-86.12K	-11.81K	-24.76K	-262.97K	-9.53K	-	-7.81K	-16.32K	-	-	-
Free Cash Flow	-	-	-	-19.25M	-30.12M	-44.99M	-	-	-56.65M	-30.33M	-43.21M	-33.35M
Net Change in Cash	-	-	-	-	-	-	-	-	-85.37M	-1.60M	-88.30M	15.51M

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-
ROE %	-32.5%	-82.5%	-48.6%	-86.4%	-56.4%	-44.9%	-126.5%	-63.1%	-	-41.1%	-31.3%	-78.7%	-76.5%
ROCE %	-117.1%	-97.5%	-46.0%	-81.7%	-55.1%	-45.8%	-100.7%	-51.3%	-	-37.8%	-33.9%	-69.9%	-79.7%

Shareholding Pattern

Insiders

3.18%

Institutions

62.79%

Public Float

64.86%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Knoll Capital Management, LLC	9.08%	5.48M	$9.58M
2	Blackrock Inc.	6.24%	3.76M	$6.59M
3	AQR Capital Management, LLC	4.69%	2.83M	$4.95M
4	Vanguard Capital Management LLC	3.92%	2.36M	$4.14M
5	Kingdon Capital Management LLC	3.57%	2.15M	$3.77M
6	683 Capital Management LLC	2.49%	1.50M	$2.62M
7	Shaw D.E. & Co., Inc.	2.33%	1.40M	$2.46M
8	Geode Capital Management, LLC	2.07%	1.25M	$2.19M
9	State Street Corporation	1.86%	1.12M	$1.97M
10	Millennium Management Llc	1.65%	995.24K	$1.74M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALDX

No recent headlines available.

ALDX · Healthcare